BlueCrest Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

BlueCrest Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-708	Closed	-$297K	–	1116
2019 Q1	$297K	Buy	708 +183	+35%	+$73.4K	0.01%	716
2018 Q4	$160K	Buy	+525	New	+$170K	0.01%	700

Other funds holding EIGR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

BlueCrest Capital Management's EIGR Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 708 shares — an estimated $297K sold.

BlueCrest Capital Management first reported a position in EIGR in Q4 2018 and held it in 2 quarters. The position peaked at $297K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

BlueCrest Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
BlueCrest Capital Management sold 708 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $297K.
BlueCrest Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 2 quarters.
BlueCrest Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $297K in Q1 2019.
78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.